Literature DB >> 8026035

Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats.

M Ruzicka1, B Yuan, F H Leenen.   

Abstract

BACKGROUND: The role of nonhemodynamic cardiac trophic mechanisms differs not only between different models of cardiac hypertrophy but also within the same model for development versus maintenance of cardiac hypertrophy. Our previous studies pointed to a major role for the renin-angiotensin system (RAS) as a cardiac trophic stimulus in the remodeling of the heart in response to volume overload by aortocaval shunt or minoxidil treatment. METHODS AND
RESULTS: In the present study, we evaluated the effects of blockade of the RAS by the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor blocker losartan on left ventricular (LV) and right ventricular mass and LV dilation in relation to changes in central hemodynamics during the maintenance of minoxidil and aortocaval shunt-induced cardiac hypertrophy. Both blockers similarly decreased LV end-diastolic pressure (LVEDP) and LV peak systolic pressure, whereas cardiac output remained unchanged in both models of volume overload. This suggests a major contribution of improved LV performance and decreased afterload to the decrease in cardiac preload by the two blockers rather than decreased venous return. Both blockers reversed LV hypertrophy in parallel to their effects on LVEDP in both models of volume overload. In minoxidil-treated rats, the extent of reversal in LV mass and dilation by the two blockers was similar to "spontaneous regression" after discontinuation of minoxidil treatment.
CONCLUSIONS: These results indicate that in contrast to the development phase of cardiac hypertrophy, the RAS does not contribute to the maintenance of volume overload-induced cardiac hypertrophy in these two models via direct cardiac trophic effects. The RAS, however, maintains cardiac hypertrophy indirectly by contributing to the persistence of high filling pressures.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8026035     DOI: 10.1161/01.cir.90.1.484

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2.

Authors:  Jiri Petrak; Jana Pospisilova; Miroslava Sedinova; Petr Jedelsky; Lucie Lorkova; Ondrej Vit; Michal Kolar; Hynek Strnad; Jan Benes; David Sedmera; Ludek Cervenka; Vojtech Melenovsky
Journal:  Proteome Sci       Date:  2011-11-11       Impact factor: 2.480

2.  Differential Effects of Prevention and Reversal Treatment with Lisinopril on Left Ventricular Remodelling in a Rat Model of Heart Failure.

Authors:  Gregory L Brower; Scott P Levick; Joseph S Janicki
Journal:  Heart Lung Circ       Date:  2015-03-13       Impact factor: 2.975

3.  [Therapy of chronic cardiac insufficiency with ACE inhibitors versus AT1 receptor antagonists. Is there a difference?].

Authors:  B Schieffer; H Drexler
Journal:  Herz       Date:  1997-12       Impact factor: 1.443

4.  Angiotensin II stimulates hyperplasia but not hypertrophy in immature ovine cardiomyocytes.

Authors:  N C Sundgren; G D Giraud; P J S Stork; J G Maylie; K L Thornburg
Journal:  J Physiol       Date:  2003-03-07       Impact factor: 5.182

5.  Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.

Authors:  P Kala; L Sedláková; P Škaroupková; L Kopkan; Z Vaňourková; M Táborský; A Nishiyama; S H Hwang; B D Hammock; J Sadowski; V Melenovský; J D Imig; L Červenka
Journal:  Physiol Res       Date:  2018-03-12       Impact factor: 1.881

Review 6.  Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.

Authors:  K L Goa; A J Wagstaff
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 7.  Is there an internal cardiac renin-angiotensin system?

Authors:  A H Danser; M A Schalekamp
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

8.  Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats.

Authors:  Vojtech Melenovsky; Jan Benes; Petra Skaroupkova; David Sedmera; Hynek Strnad; Michal Kolar; Cestmir Vlcek; Jiri Petrak; Jiri Benes; Frantisek Papousek; Olena Oliyarnyk; Ludmila Kazdova; Ludek Cervenka
Journal:  Mol Cell Biochem       Date:  2011-04-05       Impact factor: 3.396

9.  Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy.

Authors:  N Makino; M Sugano; T Hata; S Taguchi; T Yanaga
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

10.  Changes in β-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.

Authors:  Rajat Sethi; Qiming Shao; Bin Ren; Harjot K Saini; Nobuakira Takeda; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.